Want to see LBRX full AI Analyst Report?
Top Page
LB Pharmaceuticals, Inc.
(NASDAQ:LBRX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$49.00
▲(4.03% Upside)
Action:Reiterated
Date:07/30/26
The score is most constrained by weak financial performance (no revenue, ongoing losses and cash burn), partially offset by a markedly improved balance sheet and positive recent corporate events (new financing and accelerated Phase 3 timeline). Technical trend strength supports the score, while valuation metrics provide limited support due to negative earnings and no dividend.
Positive Factors
Major financing strengthens liquidity
The $150M financing materially improves funding capacity for late-stage trials and broader indications. It reduces near-term liquidity pressure and supports continued execution, although the equity-linked structure may still create dilution for existing shareholders.
Negative Factors
No revenue and persistent losses
The company has no demonstrated commercial revenue base and remains materially unprofitable. Until a product is approved and launched, operating costs will continue without recurring sales support, leaving results dependent on clinical progress and access to capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Major financing strengthens liquidity
The $150M financing materially improves funding capacity for late-stage trials and broader indications. It reduces near-term liquidity pressure and supports continued execution, although the equity-linked structure may still create dilution for existing shareholders.
Read all positive factors
LB Pharmaceuticals, Inc. (LBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.60B
Dividend YieldN/A
Average Volume (3M)373.58K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue GrowthN/A
EPS Growth-132.05%
CountryUS
Employees49
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding32,259,174
10 Day Avg. Volume237,278
30 Day Avg. Volume373,585
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$56.57Price Target Upside20.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.36
Revenue Forecast (FY)N/A
LB Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, th...
How the Company Makes Money
null...
LB Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -179.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.65M | -24.88M | -63.01M | -1.45M | -12.19M |
| Net Income | -85.69M | -25.20M | -63.10M | -6.28M | -14.35M |
Balance Sheet | |||||
| Total Assets | 361.69M | 312.93M | 33.53M | 45.66M | 21.49M |
| Cash, Cash Equivalents and Short-Term Investments | 327.79M | 295.21M | 28.00M | 43.29M | 21.40M |
| Total Debt | 5.22M | 3.57M | 3.70M | 0.00 | 24.15M |
| Total Liabilities | 29.34M | 11.62M | 128.09M | 80.13M | 50.30M |
| Stockholders Equity | 332.35M | 301.31M | -94.55M | -34.47M | -28.81M |
Cash Flow | |||||
| Free Cash Flow | -82.83M | -35.26M | -53.82M | -12.12M | -2.73M |
| Operating Cash Flow | -82.39M | -35.21M | -53.05M | -12.09M | -2.73M |
| Investing Cash Flow | -44.82M | -39.89M | 23.23M | -28.01M | 123.00K |
| Financing Cash Flow | 396.37M | 302.56M | 38.31M | 33.68M | 22.96M |
LB Pharmaceuticals, Inc. Risk Analysis
LB Pharmaceuticals, Inc. disclosed 86 risk factors in its most recent earnings report. LB Pharmaceuticals, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LB Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
LBRX
LB Pharmaceuticals, Inc.
47.52
30.72
182.86%
HIND
Vyome Holdings
2.23
-5.55
-71.34%
ENVB
Enveric Biosciences
1.44
-10.68
-88.12%
PBM
Psyence Biomedical
4.43
-11.70
-72.53%
SPRC
SciSparc Ltd.
5.13
-14.04
-73.24%
LB Pharmaceuticals, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
LB Pharmaceuticals Announces $150 Million Private Placement Financing
Positive
Jul 29, 2026
On July 28, 2026, LB Pharmaceuticals Inc. entered into a securities purchase agreement for a $150 million private placement of 3,577,560 common shares and pre-funded warrants for up to 715,513 additional shares, sold to a limited group of institut...
Business Operations and StrategyProduct-Related Announcements
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
Positive
Jul 22, 2026
On July 22, 2026, LB Pharmaceuticals announced that faster-than-expected enrollment in its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia will allow it to deliver topline results in the first half of 2027, earlier than its prior guidance ...
Executive/Board ChangesShareholder Meetings
LB Pharmaceuticals Stockholders Approve Directors and Auditor
Positive
Jun 9, 2026
LB Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026, where a quorum was present and shareholders voted on key governance matters. Stockholders elected three Class I directors—Robert A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.